Table 2.
Overall survival analysis on patients with thyroid cancer according to pathological types in Yantai during 2012 − 2022
| Charateristics | PTC | TC | MTC | ATC* | |||||
|---|---|---|---|---|---|---|---|---|---|
| 5-year OS (%, 95%CI) | Log-rank(p-value) | 5-year OS (%, 95%CI) | Log-rank(p-value) | 5-year OS(%, 95%CI) | Log-rank (p-value) | 1-year OS (%, 95%CI) | (%, 95%CI)Log-rank (p-value) | ||
| Diagnosis period | 2012 − 2016 | 92.57(91.40–93.76) | < 0.001 | 86.36(76.80–97.12) | 0.366 | 60.99(42.59–87.32) | 0.222 | 18.65(9.24–37.91) | 0.093 |
| 2017 − 2022 | 97.91(97.56–98.27) | 92.63(86.56–99.12) | 75.06(61.14–92.14) | 32.89(16.57–65.30) | |||||
| Gender | Male | 94.93(93.96–95.92) | < 0.001 | 84.92(73.44–98.19) | 0.209 | 61.06(44.29–84.17) | 0.051 | 26.37(10.13–68.69) | 0.066 |
| Female | 97.22(96.81–97.64) | 91.14(84.47–98.33) | 77.20(62.52–95.32) | 20.51(6.54–64.29) | |||||
| Age group(years) | < 45 | 99.00(98.63–99.37) | < 0.001 | 96.77(90.75–100) | < 0.001 | 75.00(42.59–100) | 0.746 | 1 | 0.173 |
| 45 − 64 | 97.70(97.24–98.16) | 94.47(88.55–100) | 67.99(53.67–86.13) | 22.22(6.55–75.44) | |||||
| ≥ 65 | 81.23(78.52–84.04) | 66.06(47.75–91.38) | 72.54(52.78–99.71) | 16.67(4.95–56.09) | |||||
| Place of residence | Urban | 97.88(97.49–98.27) | < 0.001 | 91.72(83.09–100) | 0.873 | 70.41(55.67–89.05) | 0.616 | 19.23(5.81–63.67) | 0.469 |
| Rural | 94.44(93.58–95.30) | 87.12(79.15–95.88) | 67.64(49.78–91.90) | 26.92(10.46–69.29) | |||||
| Occupational class | Service class | 98.46(97.24–99.70) | 0.001 | 1 | 0.674 | 96.70(30.00–100) | 0.459 | # | 0.037 |
| White-collar class | 97.13(95.51–98.78) | 1 | 89.33(64.19–95.82) | ▲ | |||||
| Blue‐collar class | 96.08(95.53–96.63) | 86.87(79.19–95.29) | 72.38(57.54–91.05) | 32.16(15.99–64.70) | |||||
| others | 97.48(96.85–98.11) | 90.40(78.18–100) | 67.25(49.31–91.71) | ▲ | |||||
| Site | Unilateral | 96.74(96.30–97.19) | < 0.001 | 92.79(87.29–95.63) | 0.012 | 69.16(57.00–83.91) | 0.759 | 22.73(9.91–52.15) | 0.227 |
| Isthmus | 74.64(67.90–82.04) | # | # | 15.66(7.25–71.14) | |||||
| Multiple | 98.11(97.44–98.78) | 96.49(95.71–100) | 80.00(51.61–100) | 50.00(12.50–100) | |||||
| Size (cm) | ≤ 3 | 97.79(97.45–98.14) | < 0.001 | 93.27(88.13–98.71) | < 0.001 | 75.55(64.15–88.98) | < 0.001 | 1 | 0.001 |
| > 3 | 53.48(47.73–59.93) | 81.44(52.22–85.93) | 53.88(38.76–62.28) | 5.00(0.74–33.78) | |||||
| TgAb (IU/ml) | < 115 | 98.82(98.44–99.20) | < 0.001 | 97.03(93.04–100) | < 0.001 | 88.97(77.77–100) | # | 1 | 0.027 |
| 115-500 | 90.22(87.64–92.88) | 77.78(54.85–100) | # | 14.29(2.33–87.69) | |||||
| > 500 | 19.20(14.19–25.99) | △ | # | 8.00(1.25–51.36) | |||||
| Lymph node metastasis | No | 98.91(98.62–99.19) | < 0.001 | 96.11(91.83–100) | < 0.001 | 73.05(61.29–87.07) | < 0.001 | 80.00(51.61–100) | 0.002 |
| Yes | 88.67(87.15–90.22) | 33.00(12.24–88.99) | ▲ | 6.67(1.04–42.59) | |||||
| AJCC stage | I | 99.83(99.72–99.94) | < 0.001 | 95.91(90.42–100) | 0.035 | 1 | 0.003 | # | 0.280 |
| II | 93.27(91.53–95.04) | 84.28(68.91–100) | 92.86(80.30–100) | 1 | |||||
| III | 79.33(76.88–81.87) | 79.62(66.30–95.61) | 45.84(28.75–73.08) | ▲ | |||||
| IV | 74.27(60.38–91.35) | 69.33(59.58–84.39) | 50.00(12.50–100) | 23.81(10.43–54.36) | |||||
| Treatment timing (months) | ≤ 3 | 97.77(97.41–98.14) | < 0.001 | 92.14(86.17–98.53) | 0.101 | 1 | 0.006 | ▲ | 0.372 |
| > 3 | 90.16(88.56–91.80) | 76.36(60.13–96.97) | 58.81(44.83–77.15) | 22.00(10.27–47.11) | |||||
| Therapeutic approach | Surgery | 96.66(96.26–97.05) | 0.094 | 90.94(85.35–96.90) | 0.061 | 69.16(57.31–83.46) | 0.546 | 25.00(11.84–52.79) | 0.060 |
| Surgery + RI | 1 | 53.33(21.42–100) | 1 | ▲ | |||||
TgAb Anti-thyroglobulin antibodies, PTC Papillary thyroid cancer, FTC Follicular thyroid cancer, MTC Medullary thyroid cancer, ATC Anaplastic thyroid cancer, RI Radioiodine
*1-year OS was calculated; All patients survived or were followed up for less than 1 year; All patients survived or were followed up for less than 5 year
#Missing observations made the calculation impossible, resulting in a lack of results